Plasma inhibitory activity against tumor necrosis factor in fulminant hepatic failure
Plasma inhibitory activity against tumor necrosis factor in fulminant hepatic failure
1. Soluble tumour necrosis factor receptors released into the circulation inhibit the effects of excess tumour necrosis factor-alpha and represent an important protective response. 2. In this study we have measured the levels of tumour necrosis factor and soluble tumour necrosis factor receptors p55 and p75 in the plasma of 10 patients with fulminant hepatic failure and 10 healthy control subjects. The capacity of the plasmas at varying dilutions to inhibit the biological activity of 1000 pg/ml of recombinant tumour necrosis factor in a tumour necrosis factor cytotoxicity assay in vitro was also determined. 3. The mean plasma levels of tumour necrosis factor in patients with fulminant hepatic failure (48.4 +/- 10.9 pg/ml) were significantly increased compared with normal control subjects (6.1 +/- 1.04 pg/ml, P < 0.01). Plasma soluble tumour necrosis factor receptors p55 and p75 were also significantly elevated in patients with fulminant hepatic failure (18.16 +/- 9.94 ng/ml and 16.06 +/- 9.93 ng/ml respectively) when compared with normal control subjects (1.28 +/- 0.24 ng/ml and 1.62 +/- 0.91 ng/ml, P < 0.001). 4. Fulminant hepatic failure plasma had a much lower capacity to inhibit tumour necrosis factor bioactivity in vitro, with a statistically significant difference between the inhibitory capacity of the fulminant hepatic failure and normal plasma seen at plasma dilutions of 1:5 and 1:20 (P < 0.05). 5. The reduced tumour necrosis factor neutralization capacity observed in fulminant hepatic failure, despite the increased levels of soluble tumour necrosis factor receptors, suggests enhanced susceptibility to the potential deleterious effects of tumour necrosis factor in fulminant hepatic failure.
77-80
Keene, H.M.
4dd82fcb-2524-4856-9f8e-6320ef5bfc2d
Sheron, N.
cbf852e3-cfaa-43b2-ab99-a954d96069f1
Goka, J.
157fa443-649d-4054-95f9-f754d9048074
Hughes, R.D.
8a9b2db0-e2da-4266-8fe5-06b371fbe6aa
Williams, R.
49181762-00c1-4043-9247-a9bcddbd04f7
1996
Keene, H.M.
4dd82fcb-2524-4856-9f8e-6320ef5bfc2d
Sheron, N.
cbf852e3-cfaa-43b2-ab99-a954d96069f1
Goka, J.
157fa443-649d-4054-95f9-f754d9048074
Hughes, R.D.
8a9b2db0-e2da-4266-8fe5-06b371fbe6aa
Williams, R.
49181762-00c1-4043-9247-a9bcddbd04f7
Keene, H.M., Sheron, N., Goka, J., Hughes, R.D. and Williams, R.
(1996)
Plasma inhibitory activity against tumor necrosis factor in fulminant hepatic failure.
Clinical Science, 90 (1), .
Abstract
1. Soluble tumour necrosis factor receptors released into the circulation inhibit the effects of excess tumour necrosis factor-alpha and represent an important protective response. 2. In this study we have measured the levels of tumour necrosis factor and soluble tumour necrosis factor receptors p55 and p75 in the plasma of 10 patients with fulminant hepatic failure and 10 healthy control subjects. The capacity of the plasmas at varying dilutions to inhibit the biological activity of 1000 pg/ml of recombinant tumour necrosis factor in a tumour necrosis factor cytotoxicity assay in vitro was also determined. 3. The mean plasma levels of tumour necrosis factor in patients with fulminant hepatic failure (48.4 +/- 10.9 pg/ml) were significantly increased compared with normal control subjects (6.1 +/- 1.04 pg/ml, P < 0.01). Plasma soluble tumour necrosis factor receptors p55 and p75 were also significantly elevated in patients with fulminant hepatic failure (18.16 +/- 9.94 ng/ml and 16.06 +/- 9.93 ng/ml respectively) when compared with normal control subjects (1.28 +/- 0.24 ng/ml and 1.62 +/- 0.91 ng/ml, P < 0.001). 4. Fulminant hepatic failure plasma had a much lower capacity to inhibit tumour necrosis factor bioactivity in vitro, with a statistically significant difference between the inhibitory capacity of the fulminant hepatic failure and normal plasma seen at plasma dilutions of 1:5 and 1:20 (P < 0.05). 5. The reduced tumour necrosis factor neutralization capacity observed in fulminant hepatic failure, despite the increased levels of soluble tumour necrosis factor receptors, suggests enhanced susceptibility to the potential deleterious effects of tumour necrosis factor in fulminant hepatic failure.
This record has no associated files available for download.
More information
Published date: 1996
Identifiers
Local EPrints ID: 79610
URI: http://eprints.soton.ac.uk/id/eprint/79610
ISSN: 0143-5221
PURE UUID: 558da99c-720c-419b-89bf-c996141dae26
Catalogue record
Date deposited: 17 Mar 2010
Last modified: 23 Feb 2023 17:42
Export record
Contributors
Author:
H.M. Keene
Author:
N. Sheron
Author:
J. Goka
Author:
R.D. Hughes
Author:
R. Williams
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics